Key result
Ticagrelor mitigated endothelial dysfunction compared to clopidogrel after loading (FBF ACh AUC ratio 0.83 vs 0.64; P=0.024) and 14 days of chronic administration (0.86 vs 0.66; P=0.027).
Why the study?
Does ticagrelor mitigate ischaemia-reperfusion induced vascular endothelial dysfunction compared to clopidogrel in healthy young males?
RCT (n=24)
Single-blind
randomized
Does ticagrelor mitigate ischaemia-reperfusion induced vascular endothelial dysfunction compared to clopidogrel in healthy young males?
Absolute Event Rate: 0.83% vs 0.64%
p-value: p=0.024
Ticagrelor exerts a greater vascular salutary effect than clopidogrel during reperfusion after an acute vascular occlusion in healthy young males, though neither completely prevents ischaemia-reperfusion injury.
Should not yet change antiplatelet selection; leaves open whether endothelial effects improve outcomes in RCTs.
Aims Animal data suggest that ticagrelor but not clopidogrel protects against tissue injury. It is unclear if this effect of ticagrelor is also detectable in humans. We studied the effect of ticagrelor and clopidogrel at standard clinical doses on endothelial dysfunction in an experimental model of forearm vascular ischaemia–reperfusion (IR) injury. Methods In a randomized, single‐blinded trial, 24 subjects underwent forearm blood flow (FBF) measurements in response to the endothelium‐dependent vasodilator acetylcholine (ACh) and to glyceryltrinitrate (GTN; endothelium‐independent) before and after a 20 min forearm ischaemia. FBF reactivity was assessed after an oral loading dose of ticagrelor or clopidogrel and after 14 days of regular intake of maintenance doses of the study medicines. In addition, the effect on platelet inhibition was evaluated using multiple electrode aggregometry. Results ACh‐induced vasodilation was impaired during reperfusion and not completely normalized by acute or chronic treatment with ticagrelor or clopidogrel (post‐ vs. pre‐ischaemia). However, ticagrelor mitigated endothelial dysfunction compared to clopidogrel after loading (FBF ACh AUC ratio post‐ vs. pre‐ischaemia: 0.83 [0.70; 0.96] vs. 0.64 [0.56; 0.72]; P = 0.024) and after chronic administration (FBF ACh AUC ratio: 0.86 [0.71; 1.00] vs. 0.66 [0.55; 0.77]; P = 0.027). As expected, GTN‐induced vasodilation was not affected by ischaemia. Ticagrelor or clopidogrel treatment inhibited platelet activation to a similar degree. Conclusion Our data indicate that ticagrelor treatment exerts a greater vascular salutary effect than clopidogrel during reperfusion after an acute vascular occlusion. IR‐induced vascular injury cannot be prevented completely by administration of these antiplatelet agents at standard clinical doses.
No takes yet. Share an insight, caveat, or question.
Weisshaar et al. (2017) conducted an RCT in Ischaemia-reperfusion induced vascular endothelial dysfunction (n=24). Ticagrelor vs. Clopidogrel was evaluated on Forearm blood flow acetylcholine AUC ratio post- vs. pre-ischaemia after loading dose (p=0.024). Ticagrelor mitigated endothelial dysfunction compared to clopidogrel after loading (FBF ACh AUC ratio 0.83 vs 0.64; P=0.024) and 14 days of chronic administration (0.86 vs 0.66; P=0.027).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: